Wise Management of Ovarian Cancer: On the Cutting Edge.
AURK inhibitors
PARP inhibitors
homologous recombination repair
metformin
next-generation sequencing
ovarian cancer
personalized treatment
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
21 May 2020
21 May 2020
Historique:
received:
29
04
2020
revised:
13
05
2020
accepted:
19
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
28
5
2020
Statut:
epublish
Résumé
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women. Two-thirds of patients present at advanced stage at diagnosis, and the estimated 5 year survival rate is 20-40%. This heterogeneous group of malignancies has distinguishable etiology and molecular biology. Initially, single-gene sequencing was performed to identify germline DNA variations associated with EOC. However, hereditary EOC syndrome can be explained by germline pathogenic variants (gPVs) in several genes. In this regard, next-generation sequencing (NGS) changed clinical diagnostic testing, allowing assessment of multiple genes simultaneously in a faster and cheaper manner than sequential single gene analysis. As we move into the era of personalized medicine, there is evidence that poly (ADP-ribose) polymerase (PARP) inhibitors exploit homologous recombination (HR) deficiency, especially in breast cancer gene 1 and 2 (
Identifiants
pubmed: 32455595
pii: jpm10020041
doi: 10.3390/jpm10020041
pmc: PMC7354604
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Oncotarget. 2017 Jun 20;8(25):40402-40411
pubmed: 28418882
Onco Targets Ther. 2017 Aug 28;10:4225-4238
pubmed: 28894379
Nat Genet. 2012 Apr 26;44(5):475-6; author reply 476
pubmed: 22538716
Breast Cancer Res. 2014 Jun 03;16(3):211
pubmed: 25093514
Oncotarget. 2016 Jun 7;7(23):35132-43
pubmed: 27147567
N Engl J Med. 2010 Oct 14;363(16):1532-43
pubmed: 20942669
Anticancer Res. 2015 Dec;35(12):6713-22
pubmed: 26637887
Nat Genet. 2017 May;49(5):680-691
pubmed: 28346442
J Minim Invasive Gynecol. 2014 Jan-Feb;21(1):55-63
pubmed: 23962574
Nat Genet. 2006 Nov;38(11):1239-41
pubmed: 17033622
J Clin Oncol. 2019 Nov 10;37(32):2968-2973
pubmed: 31173551
Obstet Gynecol. 2008 May;111(5):1161-6
pubmed: 18448750
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
J Clin Oncol. 2005 Sep 20;23(27):6549-55
pubmed: 16170162
Nat Rev Mol Cell Biol. 2003 Nov;4(11):842-54
pubmed: 14625535
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
Gynecol Oncol. 2017 Aug;146(2):346-350
pubmed: 28499649
Cancer Cell. 2012 Feb 14;21(2):196-211
pubmed: 22340593
Crit Rev Oncol Hematol. 2019 Feb;134:46-55
pubmed: 30771873
Obstet Gynecol. 2006 May;107(5):1075-85
pubmed: 16648414
Gynecol Oncol. 2012 Nov;127(2):390-7
pubmed: 22864111
Asian Pac J Cancer Prev. 2015;16(16):6973-9
pubmed: 26514477
Gynecol Oncol. 2018 Oct;151(1):61-68
pubmed: 30170975
Am J Obstet Gynecol. 2015 Apr;212(4):479.e1-479.e10
pubmed: 25446664
Cancer Immunol Res. 2018 Oct;6(10):1274-1287
pubmed: 30087115
Am J Surg Pathol. 1983 Apr;7(3):233-43
pubmed: 6837833
Mol Carcinog. 2019 Nov;58(11):2161-2174
pubmed: 31486135
Invest New Drugs. 2020 Feb;38(1):181-193
pubmed: 31650446
N Engl J Med. 2017 May 11;376(19):1835-1848
pubmed: 28489996
Front Oncol. 2013 Mar 20;3:58
pubmed: 23519775
Oncol Rep. 2012 Jun;27(6):1873-8
pubmed: 22469973
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
JAMA. 2019 May 21;321(19):1926-1927
pubmed: 31009043
Oncogene. 2012 Jul 5;31(27):3213-22
pubmed: 22037215
Medicine (Baltimore). 2017 Jul;96(29):e7605
pubmed: 28723808
Future Sci OA. 2019 Aug 22;5(8):FSO410
pubmed: 31534778
Nat Commun. 2018 Feb 21;9(1):746
pubmed: 29467415
Transl Oncol. 2014 Apr 17;:
pubmed: 24746712
Mod Pathol. 2012 Jun;25(6):885-92
pubmed: 22301703
Gynecol Oncol. 2011 Nov;123(2):200-4
pubmed: 21802715
Nat Genet. 2020 Feb;52(2):187-197
pubmed: 31913353
Mol Cancer Ther. 2017 Nov;16(11):2552-2562
pubmed: 28847989
J Gynecol Oncol. 2015 Jan;26(1):40-5
pubmed: 25310854
Diagnostics (Basel). 2019 May 18;9(2):
pubmed: 31109041
Gynecol Oncol. 2013 Nov;131(2):309-14
pubmed: 23938375
Int J Biochem Cell Biol. 2005 Aug;37(8):1572-7
pubmed: 15896667
J Natl Compr Canc Netw. 2016 Feb;14(2):153-62
pubmed: 26850485
Drugs R D. 2020 Jun;20(2):55-73
pubmed: 32215876
Front Oncol. 2013 Mar 13;3:47
pubmed: 23494175
Oncotarget. 2017 Mar 28;8(13):20865-20880
pubmed: 28209916
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
JAMA. 2018 Sep 25;320(12):1266-1274
pubmed: 30264118
Mol Cancer Ther. 2011 Jan;10(1):126-37
pubmed: 21177375
Eur J Hum Genet. 2014 Nov;22(11):1305-13
pubmed: 24549055
Cancer Biol Ther. 2012 Sep;13(11):1034-41
pubmed: 22895067
Oncol Lett. 2019 Sep;18(3):2404-2411
pubmed: 31402943
Gynecol Oncol. 2017 Nov;147(2):267-275
pubmed: 28882436
Oncol Lett. 2017 Dec;14(6):7557-7564
pubmed: 29344202
Clin Cancer Res. 2018 Dec 15;24(24):6168-6174
pubmed: 30108107
Drug Des Devel Ther. 2015 Jan 09;9:425-64
pubmed: 25624750
J Clin Oncol. 2007 Jul 10;25(20):2938-43
pubmed: 17617525
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Science. 2010 Oct 8;330(6001):228-31
pubmed: 20826764
Cell. 2013 Mar 14;152(6):1344-54
pubmed: 23498941
Clin Genitourin Cancer. 2016 Dec;14(6):504-510
pubmed: 27055371
Mol Cancer. 2018 Jul 31;17(1):109
pubmed: 30064416
Anticancer Res. 2012 Aug;32(8):3037-44
pubmed: 22843871
PLoS One. 2012;7(9):e45364
pubmed: 23028963
J Transl Med. 2008 Dec 11;6:79
pubmed: 19077237
Am J Clin Oncol. 2006 Feb;29(1):12-3
pubmed: 16462496
Gynecol Oncol. 2017 Feb;144(2):396-404
pubmed: 27919574
Clin Cancer Res. 2017 Aug 1;23(15):4095-4106
pubmed: 28264872
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Oncotarget. 2017 Jul 5;8(31):50376-50392
pubmed: 28881569
Cancer Res. 2007 Nov 15;67(22):10804-12
pubmed: 18006825
Clin Transl Oncol. 2009 Dec;11(12):787-98
pubmed: 20045785
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Nat Med. 2005 Jan;11(1):63-70
pubmed: 15619626
J Ovarian Res. 2017 Feb 10;10(1):9
pubmed: 28187748
Obstet Gynecol. 2006 Sep;108(3 Pt 1):509-14
pubmed: 16946208
Mol Cell Oncol. 2015 Apr 14;3(1):e1032476
pubmed: 27308548
Cancer. 2019 Dec 15;125 Suppl 24:4623-4629
pubmed: 31967682
Abdom Radiol (NY). 2020 Jun;45(6):1762-1775
pubmed: 30941451
Diagnostics (Basel). 2019 Aug 01;9(3):
pubmed: 31374917
J Med Genet. 2009 Dec;46(12):793-802
pubmed: 19564652
Mol Hum Reprod. 2016 May;22(5):329-37
pubmed: 26832958
BJOG. 2018 Jul;125(8):1001-1008
pubmed: 29412502
Cancer. 2013 Feb 1;119(3):555-62
pubmed: 23208739
Crit Rev Oncol Hematol. 2017 Dec;120:43-51
pubmed: 29198337
Diabetes Metab Res Rev. 2015 Sep;31(6):619-26
pubmed: 25820555
Semin Oncol. 2017 Jun;44(3):187-197
pubmed: 29248130
Oncol Rep. 2012 Sep;28(3):903-8
pubmed: 22752027
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Biol Res Nurs. 2018 Mar;20(2):192-204
pubmed: 29325452
Nat Med. 2016 Feb;22(2):128-34
pubmed: 26845405
Gynecol Oncol. 2011 Jun 1;121(3):492-8
pubmed: 21388661
Clin Cancer Res. 2009 Nov 1;15(21):6694-701
pubmed: 19825950
J Natl Cancer Inst. 2015 Aug 27;107(11):
pubmed: 26315354
Obstet Gynecol. 2012 Jan;119(1):61-7
pubmed: 22183212
Oncologist. 2011;16(4):404-14
pubmed: 21406469
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Oncogene. 2014 Jan 30;33(5):539-49
pubmed: 23334327
Gynecol Oncol. 2014 Jul;134(1):20-3
pubmed: 24814467
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Clin Oncol. 2020 Mar 1;38(7):674-685
pubmed: 31841383
Crit Rev Oncol Hematol. 2017 Dec;120:34-42
pubmed: 29198336
BMC Cancer. 2018 Jul 28;18(1):767
pubmed: 30055585
Gynecol Oncol. 2013 Dec;131(3):551-4
pubmed: 24007946
Nat Genet. 2020 Feb;52(2):198-207
pubmed: 31932695
Anticancer Res. 2016 Oct;36(10):5031-5042
pubmed: 27798862
Breast Cancer. 2019 Jul;26(4):510-519
pubmed: 30725392